Vulvodynia Treatment Global Market Report 2024

The vulvodynia treatment market size has grown strongly in recent years. It will grow from $5.04 billion in 2023 to $5.41 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The expansion observed in the historical period can be attributed to factors such as increasing awareness and diagnosis of vulvodynia, changing societal attitudes towards women's health, advances in gynecological understanding and practices, and the presence of patient advocacy and support groups.

The vulvodynia treatment market size is expected to see strong growth in the next few years. It will grow to $6.94 billion in 2028 at a compound annual growth rate (CAGR) of 6.4%. The anticipated growth in the forecast period can be attributed to factors such as personalized medicine approaches, the integration of psychotherapeutic interventions in vulvodynia treatment, ongoing research on novel therapies, emphasis on patient empowerment and education, and the impact of global health initiatives. Key trends in the forecast period encompass advancements in therapeutic approaches, the application of personalized medicine and targeted therapies, integration of psychological support in treatment plans, ongoing research into novel therapeutic targets, and collaborative approaches in clinical research for vulvodynia.

The vulvodynia treatment market is anticipated to experience growth, driven by the rise in genitourinary diseases. Genitourinary diseases, affecting the reproductive and urinary systems and often associated with conditions such as diabetes or high blood pressure, have been on the increase. In the US alone, it was projected that around 444,660 individuals would receive new diagnoses of genitourinary cancers in 2022, with approximately 67,330 recorded deaths. The escalating prevalence of such diseases, including ovarian cancers, is a significant factor propelling the growth of the vulvodynia treatment market. Vulvodynia treatment primarily targets various genitourinary diseases in females, aiming to alleviate pain, reduce symptoms, and enhance patients' quality of life.

The vulvodynia treatment market is also expected to see growth due to the increasing incidence of anxiety in women. Anxiety, characterized by tension, worried thoughts, and physical changes, is linked to a higher susceptibility to vulvodynia in women. Those with high anxiety levels are four times more prone to vulvodynia, and the development of vulvodynia often exacerbates anxiety and depression. Recent data from the Mental Health Foundation indicates a notable increase in anxiety levels among women compared to men. This surge in anxiety among women is identified as a driving factor for the vulvodynia treatment market.

A significant challenge for the vulvodynia treatment market is the lack of a single treatment approach applicable to all cases. Vulvodynia comprises various subtypes, such as provoked vestibulodynia, generalized vulvodynia, and localized vulvodynia, each potentially requiring a distinct treatment strategy. For example, a pilot study on therapy with local anesthetics revealed varying effectiveness for different patients, indicating the need for personalized treatment plans. The absence of a universally effective treatment for all cases poses a hurdle to the market's growth.

Leading companies in the vulvodynia treatment market are addressing these challenges by developing innovative drugs and obtaining regulatory approvals for treating vulvodynia. Oteseconazole is one such innovative drug developed by Mycovia Pharmaceuticals Inc. This azole antifungal, available in capsule form under the name Vivjoa, received approval from the U.S. Food and Drug Administration (FDA) in July 2022. Vivjoa is prescribed to reduce the risk of recurrent vulvovaginal candidiasis (RVVC) by inhibiting yeast cell growth. The development and approval of such drugs demonstrate a commitment to providing effective and targeted treatments for chronic pain conditions associated with vulvodynia.

In August 2022, Upsher-Smith Laboratories LLC collaborated with Emphascience, Inc., aiming to expand its portfolio with high-touch generic products that address unmet patient needs. Emphascience Inc., specializing in developing novel treatments for chronic pain, entered into this partnership to bring ES-001, a potential solution, to market.

Major companies operating in the vulvodynia treatment market report are Pfizer Inc., Johnson and Johnson Pvt. Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceuticals Inc., Mylan N.V., Astellas Pharma Inc., Viatris Inc., Cipla Inc., Hikma Pharmaceuticals plc, Endo International Inc., Amneal Pharmaceuticals Inc., Stada Arzneimittel AG, Glenmark Pharmaceuticals Inc., Alkem Laboratories Limited, Cadila Pharmaceuticals Ltd., Taro Pharmaceutical Industries Ltd., Upsher-Smith Laboratories LLC, Noven Pharmaceuticals Inc., National Vulvodynia Association, Zydus Lifesciences Ltd., Depomed Inc.

North America was the largest region in the vulvodynia treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vulvodynia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the vulvodynia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vulvodynia treatment market consists of revenues earned by entities by providing services such as pelvic floor physical therapy, cognitive behavioral therapy, acupuncture, exposure therapy, supportive psychotherapy, relaxation therapies, group therapy, stress management, and self-care practices. The market value includes the value of related goods sold by the service provider or included within the service offering. The vulvodynia treatment market also includes sales of topical pain relief products, pregabalin, hydroxyzine, beta-blockers, atypical antipsychotics, and alprazolam. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The main types of drugs used in vulvodynia treatment include anticonvulsants, tricyclic antidepressants, local anesthetics, antimicrobials, hormone creams, and nerve blocks. Anticonvulsants, also known as antiepileptic drugs (AEDs), form a class of pharmaceuticals that normalize the way nerve impulses travel along nerve cells, helping prevent or treat seizures. These drugs can be administered orally, topically, or through other methods and are distributed through various channels such as hospital pharmacies, online pharmacies, and retail pharmacies.

The vulvodynia treatment market research report is one of a series of new reports that provides vulvodynia treatment market statistics, including vulvodynia treatment industry global market size, regional shares, competitors with a vulvodynia treatment market share, detailed vulvodynia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the vulvodynia treatment industry. This vulvodynia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.